Debt Financing
Black Hawk Acquisition (BKHA) issues sponsor convertible note of up to $300,000
Black Hawk Acquisition Corporation (Nasdaq: BKHA) issued a convertible note of up to $300,000 at 10% to its sponsor on August 21, 2026, disclosed in a filing on August 26, 2026.

Black Hawk Acquisition Corporation (Nasdaq: BKHA) issued a convertible promissory note of up to $300,000 to its sponsor, Black Hawk Management LLC, on August 21, 2026. The company disclosed the note in a current report filed August 26, 2026. The note bears interest at 10% a year, starting July 8, 2026, for one year. The company may request advances for working capital and extension fees, but total advances may not exceed $300,000.
Why is this important: The note can fund working capital and the extension payments that keep the deadline in place, and it falls due when the business combination closes or when the company liquidates. At a business combination, the sponsor may take cash or convert the principal into shares at $1.00 each. The sponsor has also waived any claim against the funds in the trust account.
Kent Louis Kaufman signed the August 26, 2026 filing as chief executive officer. In our view, the company now depends on its sponsor to pay for time. The quarterly report for the period ended May 31, 2026 says its extension payments were funded through unsecured convertible notes issued to the sponsor. Cash stood at $11,583 at May 31, 2026, against a working capital deficit of $2,688,676.
What the note costs and what it converts into
The note is unsecured and may be prepaid at any time without penalty on written notice. The company issued it in reliance on the exemption in Section 4(a)(2) of the Securities Act of 1933. The filing names no placement agent, underwriter or financial advisor for the note, and the only lender is the sponsor.
If the note converts, the number of shares equals the principal converted divided by $1.00, rounded up to the nearest whole share. The conversion shares would carry registration rights.
The interest period starts on July 8, 2026, which is before the note was issued on August 21, 2026. The note's maturity is tied to two events only: the business combination and liquidation. In our view, the sponsor's loan buys time rather than funding a business plan, since its proceeds are limited to working capital and extension fees.
The deadline the note helps fund
The quarterly report filed July 15, 2026 says the company may extend its termination date by up to eighteen one-month extensions. The termination date moves from June 22, 2025 to December 22, 2026, and the company deposits $0.033 per remaining public share into the trust account for each monthly extension.
The same report says certain extension payments due in December 2025 and January 2026 were funded after their respective due dates. The annual report, filed March 6, 2026, says that failing to complete a business combination within the combination period raises substantial doubt about the company's ability to continue as a going concern. The same quarterly report also says the company is current with respect to its extension payments as of the date of those financial statements.
That report also shows 2,029,500 Class A non-redeemable ordinary shares issued and outstanding as of May 31, 2026, excluding 2,124,077 Class A ordinary shares subject to redemption.
The business behind the deal
The company is a special purpose acquisition company. It has an agreement with Vesicor Therapeutics, Inc., a California corporation that describes itself as a development-stage biopharmaceutical company focused on p53-based cancer therapeutics delivered via microvesicles. The April 2025 agreement set a closing condition of at least $10,000,000 in transaction financing, and a $1,000,000 liquidated damages payment if the agreement is terminated through breach.
The annual report says the company intends to use substantially all of the net proceeds of its initial public offering and private placement, including the funds held in the trust account, for its initial business combination and related expenses.
What comes next
The next dated item in the record is the termination date of December 22, 2026. The note matures at the business combination or at liquidation, whichever comes first.
Investor Chat
Loading posts…
aibio